Sneak Preview of IsoRay, Inc. ($ISR) 4Q20 Earnings

IsoRay, Inc. (AMEX:ISR) is expected to report fourth quarter earnings results, after market close, on Thursday 17th September 2020.

Analysts polled by Thomson Reuters anticipate fourth quarter loss of $ 0.01 per share.

Looking ahead, the full year loss are expected at $ 0.04 per share on the revenues of $ 10.10 million.

Previous Quarter Performance

IsoRay, Inc. revealed loss for the third quarter of $ 0.01 per share, from the revenue of $ 2.88 million. The consensus estimates are loss of $ 0.01 per share from $ 2.55 million in revenue. The top line results outshined analysts by $ 0.33 million or 12.94 percent.

Stock Performance

Shares of IsoRay, Inc. traded up $ 0.04 or 5.69 percent on Wednesday, reaching $ 0.71 with volume of 463.90 thousand shares. IsoRay, Inc. has traded high as $ 0.73 and has cracked $ 0.68 on the downward trend

According to the previous trading day, closing price of $ 0.71, representing a 134.48 % increase from the 52 week low of $ 0.29 and a 35.85 % decrease over the 52 week high of $ 1.06.

The company has a market capital of $ 48.27 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.

Conference Call

IsoRay, Inc. will be hosting a conference call at 4:30 PM eastern time on 17th September 2020, to discuss its 4Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.isoray.com

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.